CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase II Study of Anti-PD-1 Antibody (MK-3475; Pembrolizumab) for the Treatment of Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT02767934
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:38:03.550330+00:00
- Published At
- 2020-08-11T00:00:00+00:00
- Record Updated At
- 2020-08-20
- Results Posted At
- 2020-08-11
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["B Acute Lymphoblastic Leukemia", "Minimal Residual Disease", "Recurrent Acute Lymphoblastic Leukemia", "T Acute Lymphoblastic Leukemia"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2020-08-20"- protocolSection.identificationModule.nctId
"NCT02767934"- protocolSection.identificationModule.officialTitle
"A Phase II Study of Anti-PD-1 Antibody (MK-3475; Pembrolizumab) for the Treatment of Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia"- protocolSection.statusModule.overallStatus
"TERMINATED"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2020-08-11"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.